Don J. Mahuran
Toronto, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial.
Journal: JAMA neurology
Published: June 30, 2025
Letter to the Editor.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 15, 2020
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Journal: BMC neurology
Published: September 04, 2018
Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
Journal: Human gene therapy
Published: May 21, 2016
Construction of a hybrid β-hexosaminidase subunit capable of forming stable homodimers that hydrolyze GM2 ganglioside in vivo.
Journal: Molecular therapy. Methods & clinical development
Published: December 16, 2015
Pyrimethamine Derivatives: Insight into Binding Mechanism and Improved Enhancement of Mutant β-N-acetylhexosaminidase Activity.
Journal: Journal of medicinal chemistry
Published: May 19, 2015
Lysosomal abnormalities in hereditary spastic paraplegia types SPG15 and SPG11.
Journal: Annals of clinical and translational neurology
Published: July 08, 2014
Liquid chromatography/electrospray ionisation-tandem mass spectrometry quantification of GM2 gangliosides in human peripheral cells and plasma.
Journal: Analytical biochemistry
Published: December 09, 2013
Impaired glucose tolerance in a mouse model of sidt2 deficiency.
Journal: PloS one
Published: February 07, 2013
In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside.
Journal: PloS one
Published: October 11, 2012
Last Updated: 09/26/2026